Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant


Study disease: Hematologic malignancies including, but not exclusive to, multiple myeloma, acute/chronic leukemia, lymphoma, and myelodysplastic syndrome that has relapsed after allogeneic transplant. Study Rationale: Phase 1 Safety/Dose Finding Study: To determine the safety and maximum tolerated dose of Nivolumab in combination with Tocilizumab. Study Agent Description: Tocilizumab is a monoclonal antibody and immunosuppressant; specifically, tocilizumab is an interleukin-6 (IL-6) receptor antagonist. Nivolumab is a human immunoglobulin IgG4 monoclonal antibody that binds to the PD-1 receptor of T cells blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell proliferation and allowing the immune system to attack the tumor. Number of Subjects: A maximum of 12 patients will be enrolled on this Phase 1 study. Duration of Follow-up: Patients will be followed for up to one year post-treatment for survival and response.

SparkCures ID 970
Trial Phase Phase 1
Enrollment 12 Patients
Trial Sponsors
  • Medical College of Wisconsin
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria

  1. Age≥18 years with hematological malignancies who have undergone allogeneic transplant for hematological malignancy
  2. Relapsed disease post-allogeneic transplant defined as follows i. Acute or Chronic Leukemia or myelodysplastic or myeloproliferative disorders or NK cell neoplasms: Bone marrow (BM) with ≥5% disease involvement or peripheral blood evidence of overt relapse ii. Lymphoma: BM evidence of relapsed/persistent disease or PET/CT or CT evidence of persistent/progressive lymphadenopathy consistent with active lymphoma. Active disease defined as nodal lesions greater than 20 mm in the long axis or extranodal lesions >10 mm in long and short axis or bone marrow involvement that is biopsy proven
  3. Karnofsky performance status ≥70 (See Appendix A for details)
  4. Creatinine ≤ 2x upper limit of normal (ULN)
  5. Adequate hepatic function, defined as AST and ALT ≤3 x ULN. Serum bilirubin and alkaline phosphatase ≤3 x ULN, or considered not clinically significant (e.g. Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease.
  6. Without evidence of active acute or chronic GVHD
  7. Off all immunosuppression and corticosteroids (other than replacement dose steroids defined as equivalent to a maximum of 10 mg Prednisone daily) for ≥10 days from first treatment.
  8. Off all disease targeted treatments for ≥10 days to first treatment day
  9. Able to provide written informed consent
  10. Women of child-bearing potential and men must agree to use adequate contraception for the duration of study participation and for 120 days after the last treatment with nivolumab.
  11. No FDA approved, more appropriate therapies available for disease control as determined by the treating physician

Exclusion Criteria

  1. Positive beta-HCG in female of child-bearing potential
  2. CD3 donor chimerism <5% within 4 weeks of starting study treatment
  3. Evidence of active acute or chronic GVHD and/or on treatment for GVHD.
  4. Prior administration of donor lymphocyte infusion post-allogeneic transplant within the last 6 months of study treatment
  5. History of or active autoimmune disease, or other syndrome that requires systemic steroids.
  6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab.
  7. Uncontrolled or active infections on treatment
  8. Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.
  9. Presence of ≥grade 3 non-hematologic toxicities as per CTCAE version 5 from any previous treatment unless it is felt to be due to underlying disease.
  10. Concurrent use of investigational therapeutic agents or enrollment on another therapeutic clinical trial at any institution.
    1. Minimum of 4 weeks from last dose of investigational agent
  11. Prior exposure to PD-1 or CTLA4 antibodies in the post-allogeneic transplant setting. Patients who received such agents pre-allogeneic transplant will NOT be excluded
  12. Prior exposure to daratumumab in the post-allogeneic transplant setting within 2 months of start date of treatment with this investigational protocol. Patients who received this agent pre-allogeneic transplant will NOT be excluded
  13. Concurrent therapies targeted at disease relapse. However, previous treatments for relapsed disease are allowed. Concurrent active malignancy (exceptions: treated solid malignancy in >2 years' remission, treated basal or squamous cell carcinomas of the skin)
  14. History of Crohn's disease or ulcerative colitis
  15. History of demyelinating disorder
  16. Prior intolerance or allergy to Tocilizumab

US Trial Locations

Please visit the page for historical site information.

View Centers